Rainer Hinz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6132390/publications.pdf

Version: 2024-02-01

101535 106340 4,513 100 36 65 h-index citations g-index papers 108 108 108 6370 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. Molecular Psychiatry, 2022, 27, 2019-2029.	7.9	19
2	Quantitative kinetic modelling and mapping of cerebral glucose transport and metabolism using glucoCESL MRI. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 2066-2079.	4.3	1
3	Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. Molecular Psychiatry, 2021, 26, 5398-5406.	7.9	34
4	Brain Microglial Activation Increased in Glucocerebrosidase (<scp><i>GBA</i></scp>) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	3.9	49
5	Amyloid-PET–Positive Patient With bvFTD. Neurology: Clinical Practice, 2021, 11, e952-e955.	1.6	4
6	Î'lpha 5 subunit-containing GABAA receptors in temporal lobe epilepsy with normal MRI. Brain Communications, 2021, 3, fcaa190.	3.3	5
7	Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 246-256.	6.4	27
8	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using $11\text{C-BU}99008$ PET and its relationship with amyloid load. Molecular Psychiatry, 2021, 26, 5848-5855.	7.9	43
9	Pâ€glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)â€{ 11 C]verapamil PET. Epilepsia, 2020, 61, 1472-1480.	5.1	15
10	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. Efficacy and Mechanism Evaluation, 2020, 7, 1-26.	0.7	5
11	Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects. Journal of Alzheimer's Disease, 2019, 70, 455-465.	2.6	6
12	A new perspective for advanced positron emission tomography–based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.8	16
13	Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	2.4	9
14	Quantitative Diffusion Tensor Imaging (DTI) Analysis Reveals Different Infiltrative Patterns of Oligodendrogliomas and Astrocytomas in Peri-Tumour White Matter. Neurosurgery, 2019, 84, E273-E273.	1.1	0
15	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 2019, 92, e1331-e1343.	1.1	69
16	Dual-phase [18F]florbetapir in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 304-311.	6.4	18
17	[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Annals of the Rheumatic Diseases, 2019, 78, 657-662.	0.9	24
18	Decreased GABA-A Receptor Binding in Association With \hat{I}^2 -Lactam Antibiotic Use. Clinical Nuclear Medicine, 2019, 44, 981-982.	1.3	2

#	Article	IF	Citations
19	Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro-Oncology, 2019, 21, 314-325.	1.2	59
20	Comment on " <i>In Vivo</i> [¹⁸ F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates― ACS Chemical Neuroscience, 2019, 10, 768-772.	3.5	11
21	Microglial activation, white matter tract damage, and disability in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e443.	6.0	51
22	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1432-1441.	6.4	22
23	Assessing Inflammation in Acute Intracerebral Hemorrhage with PK11195 PET and Dynamic Contrast-Enhanced MRI., 2018, 28, 158-161.		15
24	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. Biological Psychiatry, 2018, 83, 61-69.	1.3	266
25	P1â€475: NOVEL THIRD GENERATION MICROGLIAL MARKER FLUTRICICLAMIDE ([18F]GE180) IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P506.	0.8	0
26	Simplifying [18F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. EJNMMI Research, 2018, 8, 46.	2.5	4
27	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	2.7	25
28	O5â€01â€02: VOXELâ€LEVEL INTERACTION BETWEEN NFT AND AMYLOID INFLUENCES/PREDICTS THE DECLINE I OF COGNITION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1636.	RATE 0.8	0
29	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	6.2	48
30	Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. Brain, 2018, 141, 2740-2754.	7.6	143
31	In vivo quantification of glial activation in minipigs overexpressing human αâ€synuclein. Synapse, 2018, 72, e22060.	1.2	15
32	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiology of Disease, 2018, 117, 211-216.	4.4	46
33	Microglial activation in normal-appearing brain regions of patients with cerebral glioma: a cross-sectional study. Lancet, The, 2017, 389, S92.	13.7	1
34	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. Brain, 2017, 140, 2002-2011.	7.6	147
35	Test-retest reproducibility of quantitative binding measures of [11 C]Ro15-4513, a PET ligand for GABA A receptors containing alpha5 subunits. NeuroImage, 2017, 152, 270-282.	4.2	17
36	[P1–123]: STRATEGIES TO DEVELOP PARAMETRIC MAPS FOR TSPO PET TRACER [11C]â€PBR28 IN PATIENTS W MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P288.	/ITH 8.8	0

#	Article	IF	CITATIONS
37	[P1–124]: REGIONAL KINETIC MODELLING APPLICATION FOR TSPO PET TRACER [11C]PBR28. Alzheimer's and Dementia, 2017, 13, P289.	0.8	O
38	[O3–09–03]: MICROGLIAL ACTIVATION IS ASSOCIATED WITH HIGHER GREY MATTER DENSITY AND HIPPOCAMPAL VOLUME IN MCI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P921.	0.8	1
39	[O3–09–06]: MICROGLIAL ACTIVATION IN ALZHEIMER'S DISEASE DETECTED BY NOVEL THIRD GENERATION TRANSLOCATOR PROTEIN TRACER FLUTRICICLAMIDE ([18F]GE180). Alzheimer's and Dementia, 2017, 13, P922.	0.8	O
40	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology, 2017, 19, 77-89.	2.6	58
41	Brain inflammation and psoriasis: a [$<$ sup $>$ 11 $<$ /sup $>$ C]-(R)-PK11195 positron emission tomography study. British Journal of Dermatology, 2016, 175, 1082-1084.	1.5	14
42	P1-001: Flutriciclamide ([18F]GE180) Pet: First in Human Pet Study of Novel in Vivo Marker of Human Translator Protein., 2016, 12, P397-P397.		0
43	P4â€343: Cerebral Brain Perfusion in Cognitively Normal Advanced Elderly (79â€93 Years) Measured with Arterial Spin Labelling and [18F]Flutemetamol PET: A Cross Modality Comparison. Alzheimer's and Dementia, 2016, 12, P1166.	0.8	0
44	In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study. Molecular Psychiatry, 2016, 21, 1672-1679.	7.9	82
45	Flutriciclamide (¹⁸ F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine, 2016, 57, 1753-1759.	5.0	93
46	Challenges of quantification of TSPO in the human brain. Clinical and Translational Imaging, 2015, 3, 403-416.	2.1	16
47	¹⁸ F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. Journal of Nuclear Medicine, 2015, 56, 386-391.	5.0	41
48	The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An ¹¹ C-(<i>R</i>)PK11195 PET Imaging and Neuropathology Study. Journal of Nuclear Medicine, 2015, 56, 512-517.	5.0	77
49	The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2144-2149.	6.4	11
50	P2-179: DOES CEREBRAL GLUCOSE METABOLISM AND BLOOD FLOW DISSOCIATE IN EARLY STAGES OF ALZHEIMER'S DISEASE?., 2014, 10, P536-P536.		2
51	[11C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1406-1419.	6.4	55
52	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	6.4	170
53	Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. Neurolmage, 2013, 70, 423-433.	4.2	52
54	Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia. Neuropsychopharmacology, 2013, 38, 938-949.	5.4	202

#	Article	IF	CITATIONS
55	Resistance of brain glucose metabolism to thiopentalâ€induced CNS depression in newborn piglets. International Journal of Developmental Neuroscience, 2013, 31, 157-164.	1.6	4
56	P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurology, The, 2013, 12, 777-785.	10.2	155
57	Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA. Neurolmage, 2013, 64, 630-639.	4.2	42
58	A POSITRON EMISSION TOMOGRAPHY STUDY OF [18F]–FLORBETAPIR IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.205-e2.	1.9	0
59	Multiple target marker tracking for real-time, accurate, and robust rigid body motion tracking of the head for brain PET. , 2013 , , .		1
60	Quantification of Ligand PET Studies using a Reference Region with a Displaceable Fraction: Application to Occupancy Studies with [11C]-DASB as an Example. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 70-80.	4.3	30
61	Realtime markerless rigid body head motion tracking using the Microsoft Kinect. , 2012, , .		9
62	Accurate markerless respiratory tracking for gated whole body PET using the Microsoft Kinect. , 2012, , .		16
63	Optimization of Supervised Cluster Analysis for Extracting Reference Tissue Input Curves in (<i>R</i>)-[¹¹ C]PK11195 Brain PET Studies. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1600-1608.	4.3	120
64	Optimization of high resolution PET iterative reconstruction with resolution modeling for image derived input function. , 2012 , , .		1
65	Pre- and Postsynaptic Serotonergic Differences in Males with Extreme Levels of Impulsive Aggression Without Callous Unemotional Traits: A Positron Emission Tomography Study Using 11C-DASB and 11C-MDL100907. Biological Psychiatry, 2012, 72, 1004-1011.	1.3	41
66	Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?. NeuroImage, 2012, 60, 1716-1723.	4.2	36
67	Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 25.	6.2	8
68	Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 2011, 25, 1113-1122.	4.1	173
69	Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology, 2011, 213, 555-562.	3.1	65
70	The design and initial calibration of an optical tracking system using the Microsoft Kinect., 2011,,.		10
71	Detection and Quantification of Large-Vessel Inflammation with ¹¹ C-(<i>R</i>)-PK11195 PET/CT. Journal of Nuclear Medicine, 2011, 52, 33-39.	5.0	68
72	Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain. Neuropsychopharmacology, 2011, 36, 2258-2265.	5.4	35

#	Article	IF	Citations
73	Reproducibility of [11C]Choline-Positron Emission Tomography and Effect of Trastuzumab. Clinical Cancer Research, 2010, 16, 4236-4245.	7.0	52
74	Image space identification of a motion tracking tool in PET and PET/CT., 2010, , .		1
75	Tariquidar inhibition of P-glycoprotein activity in patients with temporal lobe epilepsy measured with PET and (R)-[C-11]Verapamil. Neurolmage, 2010, 52, S148.	4.2	3
76	Quantification of PET studies using a displaceable reference: Application to occupancy studies with [11C]-DASB as an example. Neurolmage, 2010, 52, S195-S196.	4.2	0
77	Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. Neurolmage, 2010, 50, 984-993.	4.2	21
78	Brain serotonin transporter binding in former users of MDMA (â€~ecstasy'). British Journal of Psychiatry, 2009, 194, 355-359.	2.8	45
79	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. Neurolmage, 2009, 48, 329-338.	4.2	23
80	Effects of Citalopram Infusion on the Serotonin Transporter Binding of $[\langle sup \rangle 11 \langle sup \rangle C]$ DASB in Healthy Controls. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1478-1490.	4.3	89
81	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 2008, 32, 412-419.	4.4	448
82	In how many kinetic classes can [¹¹ C]-(R)-PK11195 brain PET data be segmented?. , 2008, , .		0
83	Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[¹¹ C]PK11195 brain PET studies. , 2008, , .		13
84	Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain, 2007, 130, 1009-1016.	7.6	101
85	5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [¹¹ C]DASB. American Journal of Psychiatry, 2007, 164, 1858-1865.	7.2	66
86	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine test–retest data. Neurolmage, 2007, 38, 82-94.	4.2	46
87	Validation of a Tracer Kinetic Model for the Quantification of 5-HT2A Receptors in Human Brain with [11C]MDL 100,907. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 161-172.	4.3	46
88	Preferred transport of O-(2-[18F]fluoroethyl)-d-tyrosine (d-FET) into the porcine brain. Brain Research, 2007, 1147, 25-33.	2.2	18
89	Reference and target region modeling of [11C]-(R)-PK11195 brain studies. Journal of Nuclear Medicine, 2007, 48, 158-67.	5.0	216
90	Increased 5-HT _{2A} Receptor Binding in Euthymic, Medication-Free Patients Recovered From Depression: A Positron Emission Study With [¹¹ C]MDL 100,907. American Journal of Psychiatry, 2006, 163, 1580-1587.	7.2	170

#	Article	IF	CITATION
91	Wavelet variance components in image space for spatiotemporal neuroimaging data. NeuroImage, 2005, 25, 159-168.	4.2	18
92	Parametric imaging of [11C]PIB studies using spectral analysis. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S590-S590.	4.3	1
93	Towards improved test-retest reliability in quantitative ligand PET: [11C]Diprenorphine as an example. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S665-S665.	4.3	2
94	Different patterns of PIB uptake in AD patients. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S666-S666.	4.3	1
95	Age-Dependent Effects of Severe Traumatic Brain Injury on Cerebral Dopaminergic Activity in Newborn and Juvenile Pigs. Journal of Neurotrauma, 2004, 21, 1076-1089.	3.4	19
96	Developmental changes in the activities of aromatic amino acid decarboxylase and catechol-O-methyl transferase in the porcine brain: A positron emission tomography study. Neuroscience Letters, 2004, 364, 159-163.	2.1	6
97	Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. Synapse, 2003, 47, 143-151.	1.2	32
98	On the Undecidability among Kinetic Models: From Model Selection to Model Averaging. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 490-498.	4.3	115
99	Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping. Physics in Medicine and Biology, 2003, 48, 3819-3841.	3.0	36
100	Effect of hypoxia/hypercapnia on metabolism of 6-[18F]fluoro-l-DOPA in newborn piglets. Brain Research, 2002, 934, 23-33.	2.2	14